How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

346 results for

Tipranavir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

single NNRTI therapy (even if only for peri-partum treatment), or only single or dual NRTI therapy prior to starting cART. Current or prior history of etravirine (ETR) use. Current use of tipranavir/ritonavir or fosamprenavir/ritonavir. Participants receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication. Note: Any prohibited medications that decrease DTG or RPV concentrations should be discontinued for a minimum of four weeks or a minimum of three

2015 Clinical Trials

122. Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

of drugs that are known potent CYP3A4 inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, tipranavir, ritonavir, and St. John's wort. Use of drugs that are CYP3A4 substrates with narrow therapeutic indices, including but not limited aripiprazole, ergotamine, halofantrine, pimozide, triazolam, astemizole*, cisapride*, and terfenadine* (* withdrawn from U.S. market). Prior malignancy other than basal cell carcinoma. Other severe acute

2015 Clinical Trials

123. Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

after consultation with the GlaxoSmithKline study team prior to randomization. Considerations include participant's ability to attend all visits on schedule, and possible drug and study procedure compatibility). A history of use of any regimen consisting of only single NNRTI therapy (even if only for peri-partum treatment), or only single or dual NRTI therapy prior to starting cART. Current or prior history of etravirine (ETR) use. Current use of tipranavir/ritonavir or fosamprenavir/ritonavir

2015 Clinical Trials

124. Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication

(Treatment) Patients receiving intensive chemotherapy with/without stable antiretroviral therapy and Maraviroc. Patients not receiving antiretroviral therapy will start this theraphy together with Maraviroc. Drug: Maraviroc Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery. Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose

2015 Clinical Trials

125. Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

) Posaconazole (Noxafil) Ritonavir (Novir®, Kaletra) Saquinivir (Fortovase, Invirase) Telaprevir (Incivek) Telithromycin (Ketek) Voriconazole (Vfend) Troleandomycin Cobicistat Tipranavir Receiving any medications or substances that are inducers of CYP3A4; use of the following inducers are prohibited =< 7 days prior to registration Strong inducers of CYP3A4/5; > 80% decrease in AUC Avasimibe Carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR) Phenytoin (Dilantin, Phenytek) Rifampin (Rifadin) St (...) . John's wort Mitotane Rifabutin Phenobarbital Moderate inducers of CYP3A4/5; 50-80% decrease in AUC Bosentan (Tracleer) Efavirenz (Sustiva) Etravirine (Intelence) Modafinil (Provigil) Nafcillin Genistein Ritonavir Talyiraline Thioridazine Tipranavir Nevirapine (Viramune) Phenobarbital (Luminal) Rifabutin (Mycobutin) Troglitazone Patients currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched

2015 Clinical Trials

126. Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis

of childbearing potential who are pregnant or lactating, or plan on becoming pregnant Any serious or active medical or psychiatric illness, which in the opinion of the investigator, would interfere with patient treatment, assessment, or adherence to the protocol. Patients taking certain drugs will be excluded from the study: a. Drugs, which are contraindicated when rifampin is used (in addition to voriconazole): i. Antiretrovirals: fosamprenavir, atazanavir, lopinavir, saquinavir, nelfinavir, tipranavir

2015 Clinical Trials

127. 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

contraindication to the use of RBV, SOF or LDV Currently receiving zidovudine (ZDV), didanosine (ddI), stavudine (d4T) or tipranavir Acute HIV infection defined as the phase immediately following infection during which anti-HIV antibodies are undetectable Known hepatocellular carcinoma Breastfeeding or pregnancy A male participant with a pregnant female partner Receipt of colony stimulating agents, including but not limited to erythropoietin, within 42 days prior to study entry Contacts and Locations Go

2015 Clinical Trials

128. A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium

Are currently taking any hormonal therapy or have been on hormonal therapy in the past 4 weeks Are taking a drug that may significantly interact or influence the metabolism of atorvastatin Concomitant cyclosporine, gemfibrizol, telaprevir, or tipranavir/ritonavir use History of stroke or transient ischemic attack in the preceding 6 months Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff

2015 Clinical Trials

129. Antiviral Pharmacology and Adherence in Drug Users

not recommended per the SOF/LDV prescribing information (e.g., tipranavir and other P-gp inducers, tenofovir disoproxil fumarate plus cobicistat, rosuvastatin, amiodarone) Any medical condition that in the opinion of the investigators will make it challenging to adhere to the study protocol, such as unstable heart disease or cancer Chronic Hepatitis B virus Infection For females, active pregnancy or any intent to become pregnant For both sexes, an unwillingness to use contraception during the study period

2015 Clinical Trials

130. Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation

., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, saquinavir, boceprevir, telaprevir, iopinavir, fosamprenavir, darunavir, tipranavir, atazanavir, nelfinavir, amprenavir, and idinavir). Treatment with another investigational drug (planned, or taken) within 28 days prior to study treatment initiation. Known hypersensitivity to ERAs, or to any of the study treatment excipients. Any condition that prevents compliance with the protocol or adherence to therapy

2015 Clinical Trials

131. Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.

HIV RNA level. Suitable ARV include: Tenofovir (TDF) and tenofovir alafenamide (TAF) Emtricitabine (FTC) Rilpivirine Dolutegravir Elvitegravir/cobicistat Contraindicated ARV include: Efavirenz 50% reduction in velpatasvir (GS-5816) exposure Didanosine Zidovudine Tipranavir Other ARV agents may be permissible at the time of study commencement pending further drug-drug interaction studies; please discuss with Study Principal Investigator. Exclusion criteria: Subjects who meet any of the exclusion

2015 Clinical Trials

132. Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs

Inhibitors: tipranavir-ritonavir Antiarrhythmic Drugs : amiodarone (Cordarone®, Nexterone®, Pacerone®) Participants will be provided with a 12-week course of FDC LDV-SOF which will provide a near 99% likelihood of a SVR in participants who are adherent to therapy with low likelihood of significant adverse events and drug-drug interactions. In treating HCV effectively the investigators will measure changes in immune activation and gene expression that accompany HCV treatment. Study Design Go to Layout (...) drug use for at least 2 years (excluding marijuana) HIV, HCV and HBV uninfected Exclusion Criteria: HIV infection Chronic infection with Hepatitis B Uncompensated cirrhosis Required use of: Anticonvulsants: carbamazepine, oxycarbazepine, phenobarbital, and phenytoin Antimycobacterials: rifabutin, rifampin, rifapentine Herbal Supplements: St. John's wort HIV Protease Inhibitors: tipranavir-ritonavir Antiarrhythmic Drugs: amiodarone (Cordarone, Nexterone, Pacerone) Any medical condition

2015 Clinical Trials

133. Clinical and virological follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug resistant viruses. Full Text available with Trip Pro

% among those 197 with resistance data. Among them, 95.8% were diagnosed before 2003, 91.7% were Spaniards, 89.6% carried HIV-1-subtype B and 75% received mono/dual therapy as first regimen. The most common TC-DRM present in ≥50% of them were D67NME, T215FVY, M41L and K103N (retrotranscriptase) and L90M (protease). The susceptibility to darunavir, tipranavir, etravirine and rilpivirine was 67.7%, 43.7%, 33.3% and 33.3%, respectively, and all reported high resistance to didanosine, abacavir (...) and nelfinavir. Despite the presence of HIV-1 resistance mutations to the three main antiretroviral families in our paediatric cohort, some drugs maintained their susceptibility, mainly the new protease inhibitors (tipranavir and darunavir) and nonnucleoside reverse transcriptase inhibitors (etravirine and rilpivirine). These data will help to improve the clinical management of HIV-infected children with triple resistance in Spain. Copyright © 2015 European Society of Clinical Microbiology and Infectious

2015 Clinical Microbiology and Infection

134. Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

or nevirapine or etravirine or rilpivirine Tenofovir+Emtricitabine+Third agent (Including a ritonavir-boosted protease inhibitor : saquinavir or indinavir or fosamprenavir or tipranavir or darunavir or atazanavir or lopinavir Tenofovir+Emtricitabine+Third agent (Including an unboosted protease inhibitor: atazanavir or indinavir Tenofovir+Emtricitabine+Third agent (Including an integrase inhibitor raltegravir or dolutegravir or cobicistat-boosted elvitegravir Tenofovir+Emtricitabine+Third agent (Including

2014 Clinical Trials

135. A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

regimen will switch to ABC/DTG/3TC FDC and be followed for an additional 24 weeks. Individuals initially randomly assigned to ABC/DTG/3TC FDC will continue on that treatment arm for an additional 24 weeks. A pharmacokinetic (PK) substudy will be conducted at a small number of sites (approximately 10) to evaluate predose DTG concentrations as well as residual drug concentrations of efavirenz (EFV), nevaripine (NVP), amprenavir (APV) and tipranavir (TPV) in a subgroup of subjects who switch from EFV (...) , NVP, fosamprenavir/ritonavir (FPV/r) or tipranavir/ritonavir (TPV/r). Condition or disease Intervention/treatment Phase Infection, Human Immunodeficiency Virus Drug: ABC/DTG/3TC FDC Drug: Ongoing cART regimen Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 555 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: 201147: a Phase

2014 Clinical Trials

136. Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

the following sensitive cytochrome P450 (CYP) 3A4 substrate medications are excluded from the study unless they can be transferred to other medications prior to enrolling: alfentanil, aprepitant, budesonide, buspirone, conivaptan, darifenacin, darunavir, dronedarone, eletriptan, eplerenone, felodipine, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, quetiapine, saquinavir, sildenafil, simvastatin, tolvaptan, tipranavir, triazolam, ticagrelor, vardenafil

2014 Clinical Trials

137. Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers

sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02251171 Recruitment Status : Completed First Posted : September 29, 2014 Last Update Posted : September 29, 2014 Sponsor: Boehringer Ingelheim Information provided by (Responsible Party): Boehringer Ingelheim Study Details Study Description Go to Brief Summary: Study to determine the effects of steady-state Tipranavir (TPV) / Ritonavir (...) (RTV) (500mg/200mg bid) on the single-dose pharmacokinetics of Rifabutin (RFB) and to determine the effects of single-dose RFB on the steady-state pharmacokinetics of TPV 500mg (co-administered with RTV 200mg) Condition or disease Intervention/treatment Phase Healthy Drug: Tipranavir Drug: Ritonavir Drug: Rifabutin Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 24 participants Intervention Model: Single Group Assignment

2014 Clinical Trials

138. Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency

: September 26, 2014 Sponsor: Boehringer Ingelheim Information provided by (Responsible Party): Boehringer Ingelheim Study Details Study Description Go to Brief Summary: To determine the pharmacokinetics of single-dose and steady-state Tipranavir/Ritonavir (TPV/r) 500/200 mg in subjects with mild to moderate hepatic insufficiency Condition or disease Intervention/treatment Phase Hepatic Insufficiency Drug: Tipranavir (TPV) Drug: Ritonavir (r) Phase 1 Study Design Go to Layout table for study information (...) Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Scheme A, mild hepatic subjects multi-dose Drug: Tipranavir (TPV) Drug: Ritonavir (r) Experimental: Scheme B, moderate hepatic subjects single dose Drug: Tipranavir (TPV) Drug: Ritonavir (r) Outcome Measures Go to Primary Outcome Measures : AUC0-∞ (area under the concentration time curve of drug in plasma over the time interval from 0 extrapolated to infinity) [ Time Frame: Up to day 12 after first

2014 Clinical Trials

139. Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV

Update Posted : September 1, 2014 Sponsor: Boehringer Ingelheim Information provided by (Responsible Party): Boehringer Ingelheim Study Details Study Description Go to Brief Summary: To determine the effect of steady-state tipranavir 500 mg/ritonavir 200 mg (TPV/r) on intracellular concentrations of zidovudine triphosphate (ZDV-TP) and carbovir triphosphate (CBV-TP) and plasma viral load Condition or disease Intervention/treatment Phase HIV Infections Drug: Tipranavir capsules Drug: Ritonavir (...) Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: TPV/r (Tipranavir co-administered with low dose ritonavir) Drug: Tipranavir capsules Drug: Ritonavir capsules Outcome Measures Go to Primary Outcome Measures : AUC0-12h (Area under curve) of intracellular ZDV-TP [ Time Frame: Up to 12 hours after drug administration ] AUC0-12h (Area under curve) of carbovir-TP [ Time Frame: Up to 12 hours after

2014 Clinical Trials

140. A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

regimen will switch to ABC/DTG/3TC FDC and be followed for an additional 24 weeks. Individuals initially randomly assigned to ABC/DTG/3TC FDC will continue on that treatment arm for an additional 24 weeks. A pharmacokinetic (PK) substudy will be conducted at a small number of sites (approximately 10) to evaluate predose DTG concentrations as well as residual drug concentrations of efavirenz (EFV), nevaripine (NVP), amprenavir (APV) and tipranavir (TPV) in a subgroup of subjects who switch from EFV (...) , NVP, fosamprenavir/ritonavir (FPV/r) or tipranavir/ritonavir (TPV/r). Condition or disease Intervention/treatment Phase Infection, Human Immunodeficiency Virus Drug: ABC/DTG/3TC FDC Drug: Ongoing cART regimen Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 555 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: 201147: a Phase

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>